Our comprehensive analysis of the GuardantINFORMTM database, to our knowledge the largest cohort studied to date for evaluating BRAF frequency, reinforced the clinical prevalence of BRAF alterations in NSCLC, particularly Class II and III mutations with high unmet therapeutic need. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.